ARENA PHARMACEUTICALS INC (ARNA) Forecast, Price Target & Analyst Ratings

NASDAQ:ARNA

99.99

+0.06 (+0.06%)

At close: Mar 10, 2022

99.99

0 (0%)

After Hours: 3/10/2022, 8:10:48 PM

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ARENA PHARMACEUTICALS INC (ARNA).

Consensus Price Target

Price Target

$99.80

-0.19% Downside

→ Price target details

Next Earnings Forecast

Earnings Estimate

Release Date: May 3, 2022
Period: Q1 / 2022
EPS Estimate: -$2.26
Revenue Estimate: 863.603K

→ Full earnings forecast details

ChartMill Buy Consensus

Rating

69.47%

Weighted Analyst Rating Score

→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target

$99.80

Upside

-0.19%

From current price of $99.99 to mean target of $99.80, Based on 19 analyst forecasts

Low

$80.80

Median

$102.00

High

$110.25

Price Target Revisions

1 Month

N/A

3 Months

N/A

Price Target Summary

19 Wall Street analysts provided a forecast for the next 12 months for ARNA. The average price target is 99.8 null. This implies a price decrease of -0.19% is expected in the next year compared to the current price of 99.99.

→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

Analyst Ratings History

Analyst Ratings Consensus

ChartMill Buy Consensus

69.47%

ARNA was analyzed by 19 analysts. The buy percentage consensus is at 69. So analysts seem to be have mildly positive about ARNA.

In the previous month the buy percentage consensus was at a similar level.

ARNA was analyzed by 19 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.

→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Date	Firm	Action	From → To
2022-02-09	HC Wainwright & Co.	Downgrade	Buy -> Neutral
2021-12-21	Cantor Fitzgerald	Downgrade	Overweight -> Neutral
2021-12-14	JMP Securities	Downgrade	Market Outperform -> Market Perform
2021-12-14	RBC Capital	Downgrade	Outperform -> Sector Perform
2021-12-14	SVB Leerink	Downgrade	Outperform -> Market Perform
2021-12-14	Credit Suisse	Downgrade	Outperform -> Neutral
2021-12-14	Citigroup	Downgrade	Buy -> Neutral
2021-12-14	Jefferies	Downgrade	Buy -> Hold
2021-12-13	Needham	Downgrade	Buy -> Hold
2021-12-08	Wells Fargo	Initiate	Overweight
2021-08-10	Cantor Fitzgerald	Maintains	Overweight
2021-08-06	Credit Suisse	Maintains	Outperform
2021-05-18	Goldman Sachs	Initiate	Buy
2021-05-07	SVB Leerink	Maintains	Outperform
2021-04-27	Citigroup	Initiate	Buy
2021-04-13	Credit Suisse	Maintains	Outperform
2021-03-26	HC Wainwright & Co.	Maintains	Buy
2021-03-03	Cantor Fitzgerald	Maintains	Overweight
2021-02-24	SVB Leerink	Maintains	Outperform

Next Earnings Forecast Details

Next Earnings Details

Release Date: May 3, 2022
Period: Q1 / 2022
EPS Estimate: -$2.26
Revenue Estimate: 863.603K
Revenue Q2Q: N/A
EPS Q2Q: -14.04%
Number of Analysts: 10

Next Earnings Revisions

Revenue (1 Month)

N/A

Revenue (3 Months)

N/A

EPS (1 Month)

N/A

EPS (3 Months)

N/A

Next Earnings Summary

ARNA is expected to report earnings on 5/3/2022. The consensus EPS estimate for the next earnings is -2.26 null and the consensus revenue estimate is 863.60K null.

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

	2019	2020	2021	2022	2023	2024	2025
Revenue YoY % growth	806.4M 4,380.00%	300K -99.96%	54K -82.00%	31.031M 57,365.27%	90.683M 192.23%	222.263M 145.10%	555.656M 150.00%
EBITDA YoY % growth	500.5M 454.96%	-422.8M -184.48%	-541.789M -28.14%	N/A	N/A	N/A	N/A
EBIT YoY % growth	497.3M 443.44%	-426.7M -185.80%	-545.661M -27.88%	N/A	N/A	N/A	N/A
Operating Margin	61.67%	-142,233.33%	-1,010,483.33%	N/A	N/A	N/A	N/A
EPS YoY % growth	7.88 363.55%	-7.40 -193.91%	-8.84 -19.46%	-8.61 2.60%	-8.28 3.82%	-8.86 -6.95%	-9.66 -9.09%

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

	Q1 / 22	Q2 / 22	Q3 / 22	Q4 / 22
EPS Q2Q % growth	-2.26 -14.04%	-2.30 4.02%	-2.40 -16.03%	-2.42 -1.21%
Revenue Q2Q % growth	863.603K	863.603K	863.603K	1.255M 2,223.33%
EBITDA Q2Q % growth	N/A	N/A	N/A	N/A
EBIT Q2Q % growth	N/A	N/A	N/A	N/A

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year

-0.06%

EPS Next 5 Year

-2.25%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year

597.10%

Revenue Next 5 Year

439.46%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year

N/A

EBIT Next 5 Year

N/A

→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

ARENA PHARMACEUTICALS INC / ARNA Forecast FAQ

Can you provide the average price target for ARENA PHARMACEUTICALS INC stock?

19 analysts have analysed ARNA and the average price target is 99.8 null. This implies a price decrease of -0.19% is expected in the next year compared to the current price of 99.99.

When does ARENA PHARMACEUTICALS INC (ARNA) report earnings?

ARENA PHARMACEUTICALS INC (ARNA) will report earnings on 2022-05-03.

What are the consensus estimates for ARENA PHARMACEUTICALS INC (ARNA) next earnings?

The consensus EPS estimate for the next earnings of ARENA PHARMACEUTICALS INC (ARNA) is -2.26 null and the consensus revenue estimate is 863.60K null.

What is the expected long term growth rate for ARENA PHARMACEUTICALS INC (ARNA)?

The expected long term growth rate for ARENA PHARMACEUTICALS INC (ARNA) is 597.1%.

Analyst forecast overview

Forecast Snapshot